John Patterson, MD
Cardiovascular Disease · Abingdon, VANPI 1073573226
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,415 of the $75,117 with a category attached, or 85.8%. 37 manufacturers reported payments, led by Johnson & Johnson at 50.7% of the total. Reporting peaked in 2019 at $31,630 and has fallen 97.8% since, to $706 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $180.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$38K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$28K
- E.r. Squibb & Sons, L.L.C.$4K
- Novartis$819
- AstraZeneca$596
- Amgen$378
- plus $3K from 31 others
What the payments were for
- Consulting fees$8001%
- Speaking & faculty fees$64,41586%
- Travel & lodging$1,8462%
- Food & beverage$8,00311%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 71 | $38,104 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 77 | $28,106 |
| E.r. Squibb & Sons, L.L.C. | 35 | $3,877 |
| Novartis | 46 | $819 |
| AstraZeneca | 32 | $596 |
| Amgen | 22 | $378 |
| Merck | 19 | $364 |
| Irhythm Technologies, Inc. | 7 | $350 |
| Boehringer Ingelheim | 14 | $257 |
| Abbott | 10 | $204 |
| Boston Scientific | 7 | $185 |
| Medtronic(2 entities) | 6 | $180 |
| Penumbra, Inc. | 3 | $153 |
| Pfizer | 9 | $152 |
| La Jolla Pharmaceutical Company | 2 | $132 |
| Lexicon Pharmaceuticals, Inc. | 5 | $126 |
| Novo Nordisk | 6 | $124 |
| Astellas Pharma US Inc | 6 | $117 |
| Sanofi-aventis U.S. LLC | 6 | $105 |
| EKOS Corporation | 2 | $98 |
| Philips North America LLC | 3 | $93 |
| Lundbeck LLC | 4 | $89 |
| Bayer | 5 | $89 |
| Cardiovascular Systems Inc. | 1 | $81 |
| Inari Medical, Inc. | 3 | $64 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $51 |
| Shockwave Medical, Inc | 1 | $32 |
| Vifor Pharma, Inc. | 2 | $29 |
| Celonova Biosciences, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Abiomed | 1 | $24 |
| Amarin Pharma, Inc. | 2 | $24 |
| Cvrx, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Lantheus Medical Imaging, Inc. | 1 | $13 |
| Advanced Oxygen Therapy Inc. | 1 | $13 |
| Reflow Medical Inc | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$36,922
- LifeVest$27,046
- ELIQUIS$3,275
- Indigo$236
- Zio monitor$149
- ZIO XT Patch$149
- GIAPREZA$114
How this compares
$75,117 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 759 | $753,871 |
| EntrestoSacubitril/Valsartan | 223 | $235,158 |
| XareltoRivaroxaban | 194 | $189,184 |
| BrilintaTicagrelor | 244 | $183,275 |
| FarxigaDapagliflozin Propanediol | 92 | $84,250 |
| JardianceEmpagliflozin | 32 | $43,296 |
| Repatha SyringeEvolocumab | 43 | $29,896 |
| Repatha SureclickEvolocumab | 24 | $13,839 |
| Ranolazine ErRanolazine | 102 | $8,500 |
| Metoprolol Succinate | 540 | $5,714 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 161 | $4,816 |
| ClopidogrelClopidogrel Bisulfate | 422 | $3,837 |
| Carvedilol | 579 | $3,755 |
| Atorvastatin Calcium | 405 | $3,482 |
| Prasugrel Hcl | 20 | $3,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $152 | $753,871759 claims |
| AstraZenecaBrilinta, Farxiga | $596 | $267,524336 claims |
| NovartisEntresto | $819 | $235,158223 claims |
| Johnson & JohnsonXarelto | $38,104 | $189,184194 claims |
| Boehringer IngelheimJardiance | $257 | $43,29632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Abingdon
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
- Roberta ChapmanGloucester$155K
- Shaival KapadiaColonial Heights$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.